[1] |
ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan.
Comparison standard terminology for pharmaceutical dose forms
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
|
[2] |
SHEN Pan, SUN Dezhi, ZHOU Wei, GAO Yue.
Research progress in toxicity prediction of traditional Chinese medicines
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 473-479.
|
[3] |
JIANG Jiandong.
Development and clinical safety of paediatric medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
|
[4] |
WANG Zhonglan, WANG Yu, HAO Lina, HU Lihua, WANG Xiaoling, ZHAO Zhigang.
Taking wrong medicines by children and precautions
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 779-781.
|
[5] |
YU Hongli, PANG Yu, SHAO Bo, XIAO Aili, YU Dongmei.
Current Adverse Drug Reaction Reporting and Monitoring of Essential Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 766-768.
|
[6] |
WU Hao, ZHANG Bing, LIN Zhijian, ZHANG Xiaomeng.
Comparison of International Pharmacovigilance of Traditional Chinese Medicine and Natural Medicines
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 406-410.
|
[7] |
ZHU Xueyan.
Research and Application Progress of Two-dimentional Liquid Chromatography on Quality Control for Traditional Chinese Herbal Medicines
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 643-646.
|
[8] |
ZHU Lan, Shao Bo, XIA Dongsheng.
Selection and Switch-to-OTC of Chinese Patent Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 785-789.
|
[9] |
WANG Tao, WANG Dan, FAN Yan, DONG Duo.
Upgrade of EudraVigilance in the EU and Its Considerations
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(7): 411-413.
|
[10] |
WU Nan, YANG Yue.
Inspiration from EU EndraVigilance
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 230-233.
|
[11] |
LU Jing, ZHEN Jian-cun.
Analysis of Inpatient Medical Prescriptions of Oral Medicines between 2013 and 2016
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(2): 113-115.
|
[12] |
WANG Pei-jie, WANG Jia-lun, YI Zhi-wei, Dong Yan-fei, WANG Pu.
Literature Analysis of 40 Cases of Adverse Drug Reactions of Nonprescription Chinese Patent Medicines for Diseases of Throat Department
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(11): 690-692.
|
[13] |
LIU Cui-li, XIA Dong-sheng.
Discussion on the Monitoring of the Adverse Reaction and the Risk Management of Essential Medicines
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(10): 614-617.
|
[14] |
MA Ping, LI Peng-fei ,CAO Miao, DING Chun-lei ,WANG Yan, LIU Li-hong.
High Throughput and Rapid Screening for Illegally Added Chemicals in Chinese Patent Medicines and Health Products by LC-MS/MS
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(1): 19-21.
|
[15] |
XIAO Ai-li, YAN Lin, JING Chun-mei.
Field Research on the Disease Coverage of "National Essential Medicines List"
[J]. Chinese Journal of Pharmacovigilance, 2012, 9(7): 401-409.
|